Clinical trials: Adrenocortical Hyperfunction
Cushings Disease
Long Term Safety and Efficacy of Pasireotide s.c. in Patients With Cushing's Disease
This is a non-interventional, multinational, multi-center post-marketing study, to further document the safety and efficacy of pasireotide s.c. administered in routine clinical practice in patients with Cushing's disease.
- Trial name
- NCT02310269
- Testing
- Pasireotide
- Where
- 54 sites in United States, Canada and 9 more
- Volunteers
- 152 people
- Sponsor
- RECORDATI GROUP
Cushing's Disease
Efficacy and Safety of Pasireotide Administered Monthly in Patients With Cushing's Disease
This is a randomized, double-blind, multicenter, phase III study to evaluate the safety and efficacy of 2 dosing regiments of Pasireotide long acting release (LAR) in patients with Cushing's disease.
- Trial name
- NCT01374906
- Testing
- pasireotide LAR, SOM230 LAR 30 mg, SOM230 LAR 10 mg
- Where
- 82 sites in United States, Argentina and 18 more
- Volunteers
- 150 people
- Sponsor
- Novartis Pharmaceuticals
Cushing's Syndrome
Osilodrostat for the Treatment of Non-Cushing's Disease Cushing's Syndrome
This is a multi-centre, observational, non-comparative, retrospective cohort study designed to evaluate the long-term safety and effectiveness of osilodrostat in non-CD CS patients.
- Trial name
- LINC7 (NCT05633953)
- Testing
- Osilodrostat
- Where
- France
- Volunteers
- 103 people
- Sponsor
- RECORDATI GROUP
Cushing's Syndrome
Roll-over Study in Patients With Endogenous Cushing's Syndrome for LCI699
The purpose of this study is the evaluation of long-term safety of osilodrostat in patients who have already received osilodrostat treatment in a previous Global Novartis-sponsored trial and who, based on investigators'…
- Trial name
- NCT03606408
- Testing
- osilodrostat
- Where
- 56 sites in United States, Argentina and 19 more
- Volunteers
- 127 people
- Sponsor
- RECORDATI GROUP
Cushing Syndrome
A Study of the Efficacy and Safety of Relacorilant in Patients With Endogenous Cushing Syndrome
This is a Phase 3, double-blind, placebo-controlled, randomized-withdrawal study to assess the efficacy, safety and pharmacokinetics (PK) of relacorilant in patients with endogenous Cushing syndrome and concurrent type 2 diabetes…
- Trial name
- GRACE (NCT03697109)
- Testing
- Relacorilant
- Where
- 64 sites in United States, Austria and 9 more
- Volunteers
- 152 people
- Sponsor
- Corcept Therapeutics
Hypercortisolism, Cushing Syndrome
Retrospective Chart Review Study of Pediatric Patients Treated With Korlym for Cushing Syndrome
This retrospective, multi-center, chart review study will collect patient data from medical charts of pediatric patients who have been treated with Korlym for Cushing's syndrome.
- Trial name
- NCT03379363
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Corcept Therapeutics
Hypercortisolism, Diabetes Mellitus, Type 2
Study to Determine the Prevalence of Hypercortisolism in Patients With Type 2 Diabetes and Treatment With Korlym® (Mifepristone) (CATALYST)
This is a Phase 4 study with 2 parts: Part 1 (Prevalence Phase) is non-interventional and will assess the prevalence of hypercortisolism in a population with difficult to control type 2 diabetes (T2D) (hemoglobin A1c ≥7.5%)…
- Trial name
- NCT05772169
- Testing
- Mifepristone 300 MG [Korlym]
- Where
- 36 sites in United States
- Volunteers
- 1,113 people
- Sponsor
- Corcept Therapeutics
Endogenous Cushing's Syndrome
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
This is a non-interventional, multinational, multi-centre study with primary data collection, to further document the safety and efficacy of osilodrostat administered in routine clinical practice in patients treated with…
- Trial name
- LINC6 (NCT05382156)
- Testing
- Osilodrostat
- Where
- 43 sites in United States, France and 3 more
- Volunteers
- 206 people
- Sponsor
- RECORDATI GROUP
Cushing's Syndrome
A Study of the Efficacy and Safety of CORLUX in the Treatment of Endogenous Cushing's Syndrome
Patients will receive Corlux (mifepristone) daily for up to 24 weeks. Assessments of the signs and symptoms of Cushing's syndrome will be obtained.
- Trial name
- SEISMIC (NCT00569582)
- Testing
- mifepristone
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Corcept Therapeutics